TheraRadar

Lexicon

Pre-Approval PRO BETA
🟡

Slowing Activity

No new clinical trials started in 1-2 years. Monitor for changes in pipeline strategy. Last trial started: 9/24/2024

60
Total Trials
18
Phase 3
17
Phase 2
1
Recruiting
484
Score

Pipeline by Phase

Phase 3
18
Phase 2
17
Phase 1
26

Therapeutic Focus

Type 2 Diabetes Mellitus Healthy Carcinoid Syndrome Type 1 Diabetes Mellitus Drug Interactions

Clinical Trials (60)

NCT06481891 Phase 3 RECRUITING

A Study to Evaluate the Efficacy and Safety of Sotagliflozin in Symptomatic Obstructive and Non-obstructive Hypertrophic Cardiomyopathy

Started: 9/24/2024

NCT03521934 Phase 3 TERMINATED

Effect of Sotagliflozin on Cardiovascular Events in Participants With Type 2 Diabetes Post Worsening Heart Failure (SOLOIST-WHF Trial)

Started: 6/15/2018

NCT03315143 Phase 3 TERMINATED

Effect of Sotagliflozin on Cardiovascular and Renal Events in Participants With Type 2 Diabetes and Moderate Renal Impairment Who Are at Cardiovascular Risk

Started: 12/19/2017

NCT03242018 Phase 3 COMPLETED

A Study to Evaluate Safety and Effects of Sotagliflozin 400 and 200 mg on Glucose Control in Participants With Type 2 Diabetes, Severe Impairment of Kidney Function and Inadequate Blood Sugar Control

Started: 8/16/2017

NCT03386344 Phase 3 TERMINATED

Efficacy and Bone Safety of Sotagliflozin 400 and 200 mg Versus Placebo in Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control

Started: 2/19/2018

NCT03242252 Phase 3 COMPLETED

Safety and Efficacy Study of Sotagliflozin on Glucose Control in Participants With Type 2 Diabetes, Moderate Impairment of Kidney Function, and Inadequate Blood Sugar Control

Started: 8/16/2017

NCT02926937 Phase 3 COMPLETED

Efficacy and Safety of Sotagliflozin Versus Placebo in Patients With Type 2 Diabetes Mellitus Not Currently Treated With Antidiabetic Therapy

Started: 11/11/2016

NCT02926950 Phase 3 COMPLETED

Efficacy and Safety of Sotagliflozin Versus Placebo in Patients With Type 2 Diabetes Mellitus on Background of Metformin

Started: 11/1/2016

NCT03351478 Phase 3 COMPLETED

Efficacy and Safety of Sotagliflozin Versus Placebo and Empagliflozin in Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control While Taking a DPP4 Inhibitor Alone or With Metformin

Started: 11/27/2017

NCT03332771 Phase 3 COMPLETED

Efficacy and Safety of Sotagliflozin Versus Glimepiride and Placebo in Participants With Type 2 Diabetes Mellitus That Are Taking Metformin Monotherapy

Started: 12/1/2017

NCT03285594 Phase 3 COMPLETED

Efficacy and Safety of Sotagliflozin Versus Placebo in Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control While Taking Insulin Alone or With Other Oral Antidiabetic Agents

Started: 9/15/2017

NCT03066830 Phase 3 COMPLETED

Efficacy and Safety of Sotagliflozin Versus Placebo in Participants With Type 2 Diabetes Mellitus on Background of Sulfonylurea Alone or With Metformin

Started: 2/24/2017

NCT02384941 Phase 3 COMPLETED

Efficacy, Safety, and Tolerability Study of Sotagliflozin as Adjunct Therapy in Adult Patients With Type 1 Diabetes Mellitus Who Have Inadequate Glycemic Control With Insulin Therapy

Started: 3/1/2015

NCT02531035 Phase 3 COMPLETED

A Phase 3 Study to Evaluate the Safety of Sotagliflozin in Patients With Type 1 Diabetes Who Have Inadequate Glycemic Control With Insulin Therapy Alone

Started: 9/1/2015

NCT02421510 Phase 3 COMPLETED

Efficacy, Safety, and Tolerability Study of Sotagliflozin as Adjunct Therapy in Adult Patients With Type 1 Diabetes Mellitus Who Have Inadequate Glycemic Control With Insulin Therapy

Started: 5/1/2015

NCT02026063 Phase 3 COMPLETED

Telotristat Etiprate - Expanded Treatment for Patients With Carcinoid Syndrome Symptoms

Started: 1/14/2014

NCT01677910 Phase 3 COMPLETED

TELESTAR (Telotristat Etiprate for Somatostatin Analogue Not Adequately Controlled Carcinoid Syndrome)

Started: 1/8/2013

NCT02063659 Phase 3 COMPLETED

Telotristat Etiprate for Carcinoid Syndrome Therapy

Started: 3/11/2014

NCT04662281 Phase 2 COMPLETED

Efficacy and Safety of LX9211 in Participants With Postherpetic Neuralgia

Started: 12/10/2020

NCT06203002 Phase 2 COMPLETED

A Dose-ranging Study in Patients With Diabetic Peripheral Neuropathic Pain (DPNP)

Started: 11/29/2023

NCT04455633 Phase 2 COMPLETED

Efficacy, Safety, and PK of LX9211 in Participants With Diabetic Peripheral Neuropathic Pain

Started: 9/3/2020

NCT03292653 Phase 2 TERMINATED

Safety, Tolerability and Pharmacodynamic Activity of Sotagliflozin in Hemodynamically Stable Participants With Worsening Heart Failure

Started: 12/4/2017

NCT01742208 Phase 2 COMPLETED

Safety and Efficacy of Sotagliflozin (LX4211) in Patients With Inadequately Controlled Type 1 Diabetes Mellitus

Started: 2/1/2013

NCT02383940 Phase 2 COMPLETED

Efficacy and Safety of Sotagliflozin in Young Adult Patients With Type 1 Diabetes Mellitus and Elevated Hemoglobin A1C

Started: 4/1/2015

NCT02459899 Phase 2 COMPLETED

Dose-ranging Study in Patients With Type 1 Diabetes Mellitus

Started: 7/1/2015

NCT01456052 Phase 2 COMPLETED

A Study to Evaluate Safety and Efficacy of Telotristat Etiprate (LX1606) in Participants With Acute, Mild to Moderate Ulcerative Colitis

Started: 1/30/2012

NCT01104415 Phase 2 COMPLETED

Study of Telotristat Etiprate (LX1606) in Participants With Symptomatic Carcinoid Syndrome

Started: 6/15/2010

NCT00853047 Phase 2 COMPLETED

Study of Telotristat Etiprate (LX1606) in Participants With Symptomatic Carcinoid Syndrome Not Managed by Stable-Dose Octreotide Therapy

Started: 3/1/2009

NCT01494233 Phase 2 COMPLETED

A Multi-Center Trial to Determine the Safety and Efficacy of LX1033 in Subjects With Diarrhea-Predominant Irritable Bowel Syndrome

Started: 2/1/2012

NCT01376557 Phase 2 COMPLETED

Safety and Efficacy of LX4211 With Metformin in Type 2 Diabetes Patients With Inadequate Glycemic Control on Metformin

Started: 6/1/2011

NCT00903383 Phase 2 COMPLETED

Study of LX3305 in Subjects With Active Rheumatoid Arthritis on Stable Methotrexate

Started: 7/1/2009

NCT00962065 Phase 2 COMPLETED

Study of LX4211 in Subjects With Type 2 Diabetes Mellitus

Started: 8/1/2009

NCT00813098 Phase 2 COMPLETED

Study of LX1031 in Subjects With Non-Constipating Irritable Bowel Syndrome

Started: 12/1/2008

NCT00691808 Phase 2 COMPLETED

Study of LX6171 in Elderly Volunteers With Age Associated Memory Impairment

Started: 2/1/2008

NCT02647918 Phase 1 COMPLETED

Study to Evaluate Sotagliflozin in Subjects With Varying Degrees of Renal Function

Started: 12/1/2015

NCT03423446 Phase 1 COMPLETED

Study to Evaluate the Pharmacokinetics of Telotristat Ethyl in Subjects With Severe Hepatic Impairment

Started: 11/28/2017

NCT03302845 Phase 1 COMPLETED

A Phase 1 Study to Evaluate the Effects of Omeprazole and Famotidine on the Absorption of Telotristat Ethyl in Healthy Subjects

Started: 9/21/2017

NCT02471274 Phase 1 COMPLETED

PK Study of Sotagliflozin in Subjects With Hepatic Impairment

Started: 6/1/2015

NCT02195635 Phase 1 COMPLETED

Phase 1, Open-label, Drug-drug Interaction Study With Octreotide Acetate Injection and Telotristat Etiprate in Healthy Subjects

Started: 7/1/2014

NCT02373046 Phase 1 COMPLETED

Bioequivalence Study Between 400 mg LX4211 Tablets and 2 X 200 mg LX4211 Tablets

Started: 2/1/2015

NCT01528111 Phase 1 COMPLETED

Study to Evaluate the Safety, Tolerability, and Efficacy of LX7101 in Subjects With Primary Open-angle Glaucoma or Ocular Hypertension

Started: 3/1/2012

NCT02300350 Phase 1 COMPLETED

DDI Study With Multiple-dose LX4211 and Single Dose Digoxin

Started: 10/1/2014

NCT02300363 Phase 1 COMPLETED

DDI Study With Multiple-dose LX4211 and Single Dose Rosuvastatin

Started: 10/1/2014

NCT02157558 Phase 1 COMPLETED

An Open-Label Drug-Drug Interaction Study of Telotristat Etiprate and Fexofenadine in Healthy Subjects

Started: 7/1/2014

NCT02155205 Phase 1 COMPLETED

A Thorough QT Study of Telotristat Etiprate

Started: 5/1/2014

NCT02157584 Phase 1 COMPLETED

An Open-Label Food Effect Study of Telotristat Etiprate

Started: 6/1/2014

NCT02147808 Phase 1 COMPLETED

A Open-Label Drug-Drug Interaction Study of Telotristat Etiprate and Midazolam in Healthy Subjects

Started: 5/1/2014

NCT01913002 Phase 1 COMPLETED

Study to Define the Electrocardiogram Effects of a Single Dose of LX4211 in Healthy Subjects

Started: 7/1/2013

NCT01916863 Phase 1 COMPLETED

Study to Evaluate the Effect of Single Doses of LX4211 and Canagliflozin on Intestinal Glucose Absorption in Healthy Adult Subjects

Started: 8/1/2013

NCT01916850 Phase 1 COMPLETED

Study to Determine the Safety, Tolerability and Pharmacokinetics Following Multiple Doses of LX4211 in Healthy Subjects

Started: 8/1/2013

NCT01932528 Phase 1 COMPLETED

An Open-label Study to Evaluate the Absorption, Metabolism, and Excretion of [14C]-Telotristat Etiprate in Males

Started: 8/1/2013

NCT01555008 Phase 1 COMPLETED

Study to Evaluate the Pharmacodynamic and Pharmacokinetic Effects of LX4211 in Subjects With Type 2 Diabetes and Renal Impairment

Started: 3/1/2012

NCT01818232 Phase 1 COMPLETED

Study to Determine the Absorption, Metabolism, and Excretion of [14C]LX4211 in Healthy Male Subjects

Started: 3/1/2013

NCT01417052 Phase 1 COMPLETED

A Study to Determine the Safety and Efficacy of LX3305 in Subjects With Active Rheumatoid Arthritis

Started: 9/1/2011

NCT01411800 Phase 1 COMPLETED

An Open-Label Study of Two Formulations of LX1033 in Healthy Human Subjects

Started: 8/1/2011

NCT01441232 Phase 1 COMPLETED

A Study to Evaluate the Pharmacodynamic Effects of Single-Dose Co-Administration of LX4211 With Januvia® in Type 2 Diabetics

Started: 10/1/2011

NCT01334242 Phase 1 COMPLETED

A Study to Determine the Pharmacodynamics of LX4211 Relative to Meals in Healthy Subjects

Started: 3/1/2011

NCT01292993 Phase 1 COMPLETED

A Study to Evaluate the Interaction of LX4211 and Metformin in Healthy Subjects

Started: 2/1/2011

NCT01188863 Phase 1 COMPLETED

Study of Two Oral Formulations of LX4211 in Patients With Type 2 Diabetes Mellitus

Started: 9/1/2010

NCT00847886 Phase 1 COMPLETED

Study of LX3305 and Methotrexate in Subjects With Stable Rheumatoid Arthritis

Started: 2/1/2009

Drug Candidates

Sotagliflozin LX9211 LX9211 (blinded) Sotagliflozin (SAR439954) Oral Antidiabetes Drugs (OADs) Telotristat etiprate Telotristat Etiprate Octreotide LAR Depot Telotristat Ethyl Telotristat ethyl 250 mg
Activity Status: Slowing
Last Trial Started: 9/24/2024
Last Trial Ended: 2/24/2025
Trials (12 months): 0
Completed Trials: 55
Data sourced from ClinicalTrials.gov. This company has no FDA-approved drugs.